AestheticsFeatured ArticlesPhotoprotectionSkin of Color

Impact of Iron-Oxide Containing Formulations Against Visible Light-Induced Skin Pigmentation in Skin of Color Individuals

By September 9, 2020September 14th, 2020No Comments

Featured Article

Featured Article

In this study, the efficacy of two formulations containing iron oxide was evaluated in preventing visible light-induced pigmentation compared with a non-tinted mineral SPF 50+ sunscreen.

Read more

In this study, the efficacy of two formulations containing iron oxide was evaluated in preventing visible light-induced pigmentation compared with a non-tinted mineral SPF 50+ sunscreen.

Hawasatu Dumbuya PhD, Pearl E Grimes MD, Stephen Lynch PhD, Kalli Ji PhD, Manisha Brahmachary PhD, Qian Zheng Md PhD, Charbel Bouez PhD, Janet Wangari-Talbot PhD

 

 

Visible light (400–700nm), which contributes to 45% of solar radiation, contributes to skin darkening and worsening of dyschromias, particularly in individuals with Fitzpatrick skin phototypes III and higher.

The pathogenesis of melasma is incompletely understood, which poses a challenge for disease management. Causative factors include genetics, ultraviolet (UV) radiation, cosmetics, pregnancy, hormonal therapy, phototoxic drugs, and various medications.

Currently, sunscreens provide limited protection against that spectrum. Due to their capabilities in absorbing, scattering, and reflecting visible light, topical products containing pigments and/or metal oxides can provide additional photoprotection.

In this study, the efficacy of two formulations containing iron oxide was evaluated in preventing visible light-induced pigmentation compared with a non-tinted mineral SPF 50+ sunscreen. Expert grading and colorimetry demonstrated that the iron-oxide containing formulations significantly protected against visible light-induced pigmentation compared to untreated skin or mineral SPF 50+ sunscreen in Fitzpatrick IV individuals.

Read Full Article Now
Article Cited in this Post

Open Access Articles

The Journal of Drugs in Dermatology (JDD) presents Open Access content, unrestricted access to our original articles, award-winning case studies, clinical trial reviews and clearance updates, drugs and devices, and special content geared toward medical residents and other allied health professionals.
Articles are reviewed by the Editorial Board of renowned experts, from key opinion leaders to well-known clinicians. View our open-access dermatology articles now.
View All Open Access Articles

You May Also Like

Journal of Drugs in Dermatology JDD Article About Social Media as a Catalyst for Health Education and Early Diagnosis of Hidradenitis Suppurativa. Image also from the Full Spectrum of Dermatology: A Diverse and Inclusive Atlas. It features a lighter skin tone patient who has HS under arm.

Social Media as a Catalyst for Health Education and Early Diagnosis of Hidradenitis Suppurativa

| Featured Articles, Latest News, Social and Technology, The Latest | No Comments
Has TikTok Helped Your Patients Recognize Hidradenitis Suppurativa Sooner? You might have heard it from your own patients: “I saw a video on TikTok and realized I might have HS.”…
Journal of Drugs in Dermatology JDD Article About Exploring the Gut Microbiome’s Role in Drug-Induced Photosensitivity: A Need for Deeper Investigation

Exploring the Gut Microbiome’s Role in Drug-Induced Photosensitivity: A Need for Deeper Investigation

| Featured Articles, Latest News, The Latest | No Comments
Is Your Patient’s Gut Making Their Skin More Sensitive to the Sun? Drug-induced photosensitivity is nothing new, but could the gut microbiome be influencing how severely patients react to sunlight?…
Journal of Drugs in Dermatology JDD Article About Considerations on Concurrent Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Isotretinoin

Considerations on Concurrent Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists and Isotretinoin

| Acne, Featured Articles, Latest News, The Latest | No Comments
GLP-1RAs and Isotretinoin: A Risky Combination? Recent reports on dermatologic side effects of GLP-1 receptor agonists (GLP-1RAs) have prompted a closer look at how these drugs interact with other treatments,…

Leave a Reply